Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 954 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR The UK Government’s spending review: Time to invest in the future... October 20, 2020 “Scars are Tattoos with Better Stories” July 21, 2021 Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... January 22, 2025 New on NCI’s Websites for June 2023 June 29, 2023 Load more HOT NEWS PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... Scottish Soccer Star Who Just Announced Breast Cancer Diagnosis Scores Goal,... Few People with Cancer Undergo Testing for Inherited Gene Mutations Colorectal Cancer Screening: The Silver Lining
